Latest News
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
25 November 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Tuesday reported positive phase 2 results for amycretin in people with type 2 diabetes, showing statistically significant weight loss of up to 14.5% and HbA1...
Active Biotech to receive US patent for tasquinimod formulation
25 November 2025 - Swedish biotechnology company Active Biotech AB (STO:ACTI) announced on Tuesday that the US Patent and Trademark Office has confirmed it will grant a patent for a pharmaceutical formulation of tasquinimod on 2 December 2025, under ...
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
25 November 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that the European Commission has approved Dupixent (dupilumab) for adults and adolescents aged 12 and older with moderate-to-severe chroni...
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
25 November 2025 - Canadian clinical-stage biotechnology company Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) announced on Tuesday that it has begun patient enrolment at Tel Aviv Sourasky Medical Center for its FDA-approved Phase I/IIa trial of ...
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
25 November 2025 - NeuroSense Therapeutics Ltd (Nasdaq:NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced on Monday that the US Food and Drug Administration (FDA) has comple...